InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.20
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,695.74
(
0.64%
)
Post# of 77519
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

brwtrpilot

Send PM Follow Ignore
Followers 78
Posts 3789
Boards Moderated 0
Alias Born 12/21/2008

brwtrpilot

Re: None

Monday, 12/17/2012 4:38:28 AM

Monday, December 17, 2012 4:38:28 AM

Post# of 77519
On another front
Celgene has issued figures which it says demonstrate the clinical value of the NICE-agreed patient access scheme for its cancer drug Revlimid

http://www.pharmafile.com/news/176412/revlimid-patient-scheme-working?utm_source=dlvr.it&utm_medium=twitter

and this
http://www.news-medical.net/news/20121211/Celgene-announces-results-from-REVLIMID-plus-VIDAZA-phase-II-study-on-AML.aspx

and this
http://www.bloomberg.com/news/2012-12-11/celgene-s-pomalidomide-helps-in-myeloma-after-others-fail.html

Hey biotech side of the board where does the mmrg stuff fit in/??
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up